116.21
price up icon1.84%   2.07
 
loading
Abbott Laboratories stock is traded at $116.21, with a volume of 3.95M. It is up +1.84% in the last 24 hours and up +16.63% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$114.14
Open:
$114.02
24h Volume:
3.95M
Relative Volume:
0.34
Market Cap:
$201.13B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
37.56
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
+4.49%
1M Performance:
+16.63%
6M Performance:
+3.60%
1Y Performance:
-11.94%
1-Day Range:
Value
$113.45
$116.61
1-Week Range:
Value
$109.35
$116.61
52-Week Range:
Value
$81.97
$137.49

Abbott Laboratories Stock (ABT) Company Profile

Name
Name
Abbott Laboratories
Name
Phone
(224) 667-6100
Name
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Name
Employee
115,000
Name
Twitter
@AbbottNews
Name
Next Earnings Date
2026-07-16
Name
Latest SEC Filings
Name
ABT's Discussions on Twitter

Compare ABT vs SYK, MDT, BSX, EW

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ABT icon
ABT
Abbott Laboratories
116.23 198.01B 46.59B 5.41B 7.38B 3.0938
SYK icon
SYK
Stryker Corp
331.76 130.41B 25.27B 3.34B 4.57B 8.6334
MDT icon
MDT
Medtronic Plc
92.84 120.48B 36.36B 4.84B 5.43B 3.7261
BSX icon
BSX
Boston Scientific Corp
50.66 75.37B 20.62B 3.56B 3.48B 2.3847
EW icon
EW
Edwards Lifesciences Corp
89.82 53.19B 6.30B 1.07B 1.09B 1.8406

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-26 Downgrade Daiwa Securities Outperform → Neutral
Oct-10-25 Initiated The Benchmark Company Buy
Jul-18-25 Upgrade Jefferies Hold → Buy
Jun-16-25 Initiated Leerink Partners Market Perform
Oct-08-24 Initiated Oppenheimer Outperform
Sep-19-24 Initiated Piper Sandler Overweight
Jul-30-24 Downgrade Edward Jones Buy → Hold
May-30-24 Initiated Goldman Buy
Jul-21-23 Upgrade Wolfe Research Underperform → Peer Perform
May-30-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-20-23 Reiterated Barclays Overweight
Apr-20-23 Reiterated Bernstein Outperform
Apr-20-23 Reiterated JP Morgan Overweight
Apr-20-23 Reiterated Raymond James Outperform
Apr-20-23 Reiterated UBS Buy
Apr-20-23 Reiterated Wolfe Research Underperform
Mar-29-23 Initiated UBS Buy
Oct-26-22 Initiated Mizuho Neutral
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Hold
Jul-06-22 Initiated Wolfe Research Underperform
Mar-02-22 Resumed BofA Securities Buy
Jan-27-22 Reiterated Credit Suisse Outperform
Jan-27-22 Reiterated Morgan Stanley Overweight
Jan-27-22 Reiterated Raymond James Outperform
Jan-27-22 Reiterated UBS Buy
Dec-10-21 Initiated RBC Capital Mkts Outperform
Oct-27-21 Upgrade Atlantic Equities Neutral → Overweight
Oct-14-21 Initiated Redburn Neutral
May-25-21 Initiated Barclays Overweight
Apr-15-21 Initiated Atlantic Equities Neutral
Jan-28-21 Upgrade BTIG Research Neutral → Buy
Sep-11-20 Initiated Wolfe Research Outperform
Jun-01-20 Downgrade Goldman Neutral → Sell
Mar-05-20 Initiated Citigroup Buy
Feb-13-20 Initiated Goldman Neutral
Feb-06-20 Resumed BTIG Research Neutral
Jan-02-20 Downgrade Guggenheim Buy → Neutral
Jun-13-19 Reiterated BofA/Merrill Buy
Feb-07-19 Reiterated BofA/Merrill Buy
Jan-02-19 Downgrade Citigroup Neutral → Sell
Nov-30-18 Upgrade Goldman Neutral → Buy
Oct-16-18 Initiated Barclays Overweight
Jun-27-18 Initiated Bernstein Outperform
Jan-30-18 Reiterated Citigroup Neutral
Jan-25-18 Reiterated Stifel Buy
Jan-25-18 Upgrade William Blair Mkt Perform → Outperform
Jan-03-18 Initiated Evercore ISI Outperform
Jan-02-18 Upgrade JP Morgan Neutral → Overweight
Jan-02-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-19-17 Reiterated RBC Capital Mkts Outperform
Oct-19-17 Reiterated Stifel Buy
View All

Abbott Laboratories Stock (ABT) Latest News

pulisher
10:55 AM

Abbott Agrees to $670 Million Settlement in Premature Infant Formula Litigation - finance.biggo.com

10:55 AM
pulisher
09:50 AM

Analyst Raises Abbott Price Target to $135 on Strengthening Cancer Diagnostics Growth and Successful Exact Sciences Integration - TipRanks

09:50 AM
pulisher
09:46 AM

TD Cowen raises Abbott Labs stock price target on cancer diagnostics growth - Investing.com

09:46 AM
pulisher
09:36 AM

Abbott Laboratories settles multitude of infant formula legal claims - Yahoo Finance

09:36 AM
pulisher
09:20 AM

Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation - Yahoo Finance

09:20 AM
pulisher
07:48 AM

Abbott agreed to pay $670 million to settle preterm baby formula lawsuits - qz.com

07:48 AM
pulisher
06:38 AM

Abbott Laboratories stock holds firm after Q2 beat - Ad-hoc-news.de

06:38 AM
pulisher
06:00 AM

Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies - Times West Virginian

06:00 AM
pulisher
04:44 AM

True North Advisors LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat

04:44 AM
pulisher
04:02 AM

Asset Advisors Investment Management LLC Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat

04:02 AM
pulisher
03:41 AM

Exchange Traded Concepts LLC Has $6.85 Million Stock Position in Abbott Laboratories $ABT - MarketBeat

03:41 AM
pulisher
03:41 AM

Abbott Laboratories $ABT Stock Position Raised by Financial & Tax Architects LLC - MarketBeat

03:41 AM
pulisher
03:33 AM

Capital Investment Advisory Services LLC Sells 12,335 Shares of Abbott Laboratories $ABT - MarketBeat

03:33 AM
pulisher
03:30 AM

ABN Amro Investment Solutions Purchases 19,480 Shares of Abbott Laboratories $ABT - MarketBeat

03:30 AM
pulisher
03:10 AM

Alecta Tjanstepension Omsesidigt Acquires 153,500 Shares of Abbott Laboratories $ABT - MarketBeat

03:10 AM
pulisher
Aug 20, 2026

Abbott Inks $670M Deal To End Some Preterm Formula Claims - Law360

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott Will Pay $670 Million To End 2,000 Infant Formula Claims - NDTV Profit

Aug 20, 2026
pulisher
Aug 20, 2026

Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative? - simplywall.st

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott to pay $670 million to settle some preterm infant formula cases - Reuters

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott Reaches $670 Million Settlement in Infant Formula Litigation - Devdiscourse

Aug 20, 2026
pulisher
Aug 20, 2026

Can Abbott Laboratories (ABT)’s Instinct Sensor Give MiniMed Group (MMED) a Competitive Edge? - Yahoo Finance

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott Laboratories Reaches $670 Million Settlement in NEC Infant Formula Lawsuits - Kalkine Media

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott to Pay $670 Million to Settle Baby-Formula Litigation - WSJ

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott agrees to $670 million settlement of infant formula cases - The Lufkin Daily News

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott settles preterm formula litigation for $670 million By Investing.com - Investing.com Canada

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott's $670 Million Settlement Resolves Infant Formula Legal Claims - Devdiscourse

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott in $670M settlement for some NEC infant formula claims (ABT:NYSE) - Seeking Alpha

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott agrees to pay ~$670M to resolve Gill case and ~2,000 related preterm formula claims - TradingView

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott settles $670M lawsuits over preterm infa... - Pluang

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott Will Pay $670 Million to End 2,000 Infant Formula Claims - Bloomberg.com

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants - PR Newswire

Aug 20, 2026
pulisher
Aug 20, 2026

Abbott pays $670 million to settle 2,000 baby formula claims - Crain's Chicago Business

Aug 20, 2026
pulisher
Aug 20, 2026

MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor - Yahoo! Finance Canada

Aug 20, 2026
pulisher
Aug 20, 2026

Avricore and Abbott Labs sign UK pharmacy testing deal | 2026-08-20 | Investing News - Stockhouse

Aug 20, 2026
pulisher
Aug 20, 2026

Mirae Asset Global Investments Co. Ltd. Raises Position in Abbott Laboratories $ABT - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT - MarketBeat

Aug 20, 2026
pulisher
Aug 20, 2026

Citizens National Bank Trust Department Acquires 11,285 Shares of Abbott Laboratories $ABT - MarketBeat

Aug 20, 2026
pulisher
Aug 19, 2026

Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? - Yahoo Finance

Aug 19, 2026
pulisher
Aug 19, 2026

Abbott settles appeal of $495 million infant formula verdict - Investing.com

Aug 19, 2026
pulisher
Aug 19, 2026

Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch

Aug 19, 2026
pulisher
Aug 19, 2026

Richard W. Allen of Georgia’s 12th district makes significant trades in Abbott Laboratories and Advanced Micro Devices - Investing.com India

Aug 19, 2026
pulisher
Aug 19, 2026

Abbott Laboratories (ABT) Could Be 5% Undervalued Following MiniMed Pump Launch - simplywall.st

Aug 19, 2026
pulisher
Aug 19, 2026

UnitedHealth Stock And 2 Dividend Names For Investors Seeking Stability - simplywall.st

Aug 19, 2026
pulisher
Aug 19, 2026

Abbott settles appeal over $495 million infant formula verdict - Reuters

Aug 19, 2026
pulisher
Aug 19, 2026

Abbott Laboratories posts 4.8% sales growth in Q2 2026, driven by nutrition, diagnostics, and devices. - Pluang

Aug 19, 2026
pulisher
Aug 19, 2026

Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst - The Globe and Mail

Aug 19, 2026
pulisher
Aug 19, 2026

Abbott Laboratories: Diagnostics And Medical Devices Fuel Next Growth Phase (Downgrade) - Seeking Alpha

Aug 19, 2026
pulisher
Aug 19, 2026

The Smartest Dividend ETF to Buy With $500 Right Now - The Globe and Mail

Aug 19, 2026
pulisher
Aug 19, 2026

5 questions on Abbott’s glucose-ketone sensors - MedTech Dive

Aug 19, 2026
pulisher
Aug 19, 2026

Abbott Laboratories raises earnings outlook aft... - Pluang

Aug 19, 2026
pulisher
Aug 19, 2026

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? - The Motley Fool

Aug 19, 2026

Abbott Laboratories Stock (ABT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
SYK SYK
$331.98
price up icon 1.17%
MDT MDT
$92.94
price up icon 0.68%
BSX BSX
$50.66
price up icon 2.62%
EW EW
$89.86
price up icon 0.01%
$91.66
price up icon 1.58%
Cap:     |  Volume (24h):